Ratings aap Implantate AG

Equities

AAQ1

DE000A3H2101

Market Closed - Xetra Other stock markets 09:06:10 17/05/2024 pm IST			5-day change	1st Jan Change
1.39 ^EUR	+3.73%		+5.30%	+67.47%

2021	Aap Implantate AG Announces Sales Results for the Second Quarter and Half Year Ended 30 June 2021	CI
2021	Aap Implantate Ag Reports Earnings Results for the Full Year Ended December 31, 2020	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
AAP IMPLANTATE AG	+67.47%	1.49Cr	-
ABBOTT LABORATORIES	-5.43%	18TCr	C+
MEDTRONIC PLC	+4.30%	11TCr	C
BECTON, DICKINSON AND COMPANY	-3.09%	6.83TCr	A
DEXCOM, INC.	+5.86%	5.22TCr	B-
CENCORA, INC.	+8.15%	4.43TCr	B-
HOYA CORPORATION	+7.52%	4.27TCr	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	3.25TCr	B
TERUMO CORPORATION	+17.85%	2.6TCr	A-
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	2.59TCr	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes